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Introduction {#sec1}
============

Patient-specific, induced pluripotent stem cells (iPSCs) present an attractive starting point for generation of autologous hematopoietic stem cells (HSCs) for treating certain hematologic diseases in the future ([@bib24], [@bib58]). However, directed differentiation toward HSCs has remained inefficient, indicating that some key requirements necessary for full hematopoietic specification, *in vitro*, are still ill-defined, likely owing to our incomplete knowledge of HSC development, *in vivo*.

During embryonic development, definitive, multipotent HSCs are formed by a subset of cells lining the ventral floor of the dorsal aorta termed hemogenic endothelial (HE) cells ([@bib4], [@bib18], [@bib54], [@bib65]). Endothelial and blood cells share a similar gene expression pattern and emanate from common mesodermal progenitors ([@bib19], [@bib30], [@bib60]). When isolated from embryos or differentiating embryonic stem cell (ESC) cultures, these progenitors, so-called hemangioblasts, form blast colonies, *in vitro*, containing both endothelial and hematopoietic progenitors ([@bib7], [@bib21]), and, in some reports, even smooth muscle cells ([@bib9]). During blast colony formation, HE cells are generated as intermediate cells, which subsequently undergo endothelial-to-hematopoietic transition (EHT) ([@bib28]).

Several transcription factors (TFs) are known to be important intrinsic regulators of endothelial as well as HSC development, such as SCL/TAL1, ETV2, GATA2, or MEIS1 ([@bib3], [@bib5], [@bib31], [@bib32]). However, for the enforced generation of sufficient numbers of HSCs from differentiating pluripotent stem cells, *in vitro*, the instructive regulatory networks controlling separation of the endothelial and hematopoietic lineages and the critical time points of their action need to be identified. Single-cell transcriptional profiling during early mesoderm development has turned out to be a key approach for this purpose, allowing for an improved distinction of endothelial cells and hematopoietic progenitors during early mesodermal differentiation ([@bib35], [@bib49], [@bib52]). Some of the identified hematopoiesis-associated genes are involved in a regulatory network controlling *Runx1* transcription, which is essential for the formation of adult definitive HSCs by directly controlling EHT ([@bib26], [@bib28], [@bib38]). Because only limited numbers of HSCs are present in embryos ([@bib53]), the availability of HE cells may be a crucial bottleneck for the *de novo* generation of HSCs. Therefore, adequate numbers of HE cells likely need to be generated for the formation of sufficient numbers of HSCs, *in vitro*.

Except one report describing the development of hematopoietic stem and progenitor cells (HSPCs) from genetically unmanipulated ESCs ([@bib41]), significant and stable long-term repopulation of pluripotent stem cell-derived HSPCs has only been achieved using mouse cells, and only when the homeotic selector protein HOXB4 was ectopically expressed ([@bib6], [@bib25], [@bib29], [@bib33], [@bib42]). However, differentiation of transplanted HSPCs was skewed toward myelopoiesis with a concomitant inhibition of lymphopoiesis and erythropoiesis in a dose-dependent manner, suggesting either an incomplete maturation of ESC-derived HSPCs and/or active interference with transcriptional circuitries controlling differentiation ([@bib25], [@bib42], [@bib46]). Although we, and others, have identified target genes of HOXB4 in differentiating mouse ESCs ([@bib11], [@bib16], [@bib39], [@bib47]), these findings have not yet led to a satisfying explanation on how HOXB4 promotes HSPC development, *in vitro*. The most likely reason is that the activities of HOX proteins, as modulators of transcription, are highly context dependent and influenced by the microenvironment of a given cell ([@bib1], [@bib47], [@bib62]). So far, the cellular stage at which HOXB4 unfolds its activities during hematopoiesis, *in vitro*, is not yet known. Thus, its identification would be a prerequisite for unambiguously identifying the key molecular circuitries driving hematopoietic development and for the *in vitro* generation of HSPCs from pluripotent stem cells.

In this work, we demonstrate that HOXB4 promotes the generation of early hematopoietic progenitors from differentiating mouse ESCs, *in vitro*, by enforcing the development of HE cells poised for the induction of EHT by RUNX1. Molecularly, it does so, at least in part, by upregulating the expression of key TFs involved in hematopoietic development.

Results {#sec2}
=======

Ectopic HOXB4 Expression Does Not Promote Mesoderm Specification {#sec2.1}
----------------------------------------------------------------

As hematopoietic cells originate from the mesoderm, we transduced *Brachyury* (Bry) reporter ESCs (GFP-Bry, kindly provided by J. Fehling, Ulm) ([@bib12]) with retroviral vectors co-expressing HOXB4 and the fluorescent protein mPlum ([Figure 1](#fig1){ref-type="fig"}A), and determined GFP as well as vascular endothelial growth factor receptor 2 (FLK-1) expression during differentiation ([@bib37]). The peak of Bry^GFP+^FLK-1^+^ cells was detected between days 3 and 4 of embryoid body (EB) development, *in vitro*. At this stage of development, ectopic expression of HOXB4 did not promote specification of Bry^GFP+^FLK-1^+^ mesodermal cells ([Figure 1](#fig1){ref-type="fig"}B). Later, however, HOXB4 strongly enhanced the formation of CD41^+^ and CD45^+^ hematopoietic progenitors after dissociation of EB day 6 GFP-Bry (EBd6) cells and subsequent co-culture on OP9 stromal cells, confirming our previous results with CCE ESCs ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}; [Movie S1a. Genesis of CD41+ Hematopoietic Cells, In Vitro, Promoted by HOXB4 (green: HOXB4, red: CD41)](#mmc4){ref-type="supplementary-material"}, [Movie S1b. Genesis of CD41+ Hematopoietic Cells, In Vitro, Promoted by HOXB4 (phase contrast)](#mmc5){ref-type="supplementary-material"}) ([@bib6], [@bib29]). These results indicate that HOXB4 first acts downstream of early mesoderm specification and upstream of hematopoietic progenitor formation during differentiation of pluripotent stem cells.Figure 1HOXB4 Does Not Promote Early Mesoderm Specification, *In Vitro*(A) Scheme depicting the gammaretroviral, FMEV-based expression vectors ([@bib29], [@bib47]). The vectors co-express a fluorescent protein (eGFP, mPlum, or tdTomato) together with HOXB4 or a 4-hydroxytamoxifen (Tam) inducible form, HOXB4^ERT2^. Co-translational separation of the proteins is mediated by the TAV-2A esterase. LTR, long terminal repeat; wPRE, woodchuck hepatitis virus posttranscriptional regulatory element.(B) Vector-transduced GFP-Bry ESCs (mPlum +/− HOXB4) were differentiated as embryoid bodies (EBs). At the indicated days, eGFP fluorescence as well as FLK-1 expression were determined by flow cytometry. The percentages of eGFP^+^FLK-1^+^ cells are shown. CCE ESCs were used as eGFP-negative controls (top row).(C) After 6 days of differentiation, GFP-Bry EBs were dissociated and 10^5^ cells each co-cultured on OP9 stoma cells for further 8 days. Contour plots of flow cytometry analysis are shown, the percentages of CD41^+^ and CD45^+^ cells are indicated. For (B) and (C), representative results of n = 3 independent experiments are shown.

HOXB4 Promotes Formation of a Hemogenic Endothelium {#sec2.2}
---------------------------------------------------

Concomitant to the marked formation of ESC-derived CD41^+^ and CD45^+^ progenitors in OP9 co-cultures, ectopic HOXB4 led to an increased number of adherent circular structures, which were associated with suspension cell clusters ([Figure 2](#fig2){ref-type="fig"}A), expressed VE-cadherin, CD31, and were capable of acetylated low-density lipoprotein uptake ([Figures 2](#fig2){ref-type="fig"}B and 2C). The suspension cells continued to proliferate only when HOXB4 was ectopically expressed and, after transplantation into immunodeficient NSG mice, mediated the typical pattern of myeloid-biased repopulation, as repeatedly reported by us and others ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D) ([@bib25], [@bib29], [@bib33], [@bib34], [@bib42], [@bib59]). The adherent circular, cobblestone-like structures were reminiscent of previously described HE colonies ([@bib8], [@bib28]). To test this notion, we used a *Runx1* knockout ESC line carrying a doxycycline-inducible *Runx1* coding sequence stably integrated into the genome (iRunx cells) ([@bib28]). These cells are blocked immediately prior to EHT due to the absence of *Runx1* expression, which is essential for transition of the HE to hematopoietic cells. Importantly, the induction of its expression rescues the generation of blood cells ([@bib28]). This system allowed us to answer the question of whether HOXB4 acts upstream of *Runx1* in promoting the hematopoietic fate and to separate RUNX1-dependent from RUNX1-independent effects of HOXB4, as well. HOXB4 overexpression in the absence of RUNX1 led to a significant accumulation of endothelial colonies ([Figure 2](#fig2){ref-type="fig"}D). To test if these cells are truly hemogenic, we induced *Runx1* expression by addition of doxycycline to the cultures ([Movie S2a. Endothelial-to-Hematopoietic Transition of HOXB4+ Hemogenic Endothelium (without Runx induction)](#mmc6){ref-type="supplementary-material"}, [Movie S2b. Endothelial-to-Hematopoietic Transition of HOXB4+ Hemogenic Endothelium (after Runx1 induction)](#mmc7){ref-type="supplementary-material"}). After *Runx1* induction, EHT of the endothelium cells initiated with a concomitant strong upregulation of CD41 expression, particularly when HOXB4 was activated ([Figure 2](#fig2){ref-type="fig"}E). Between day 5 and 12, a subpopulation of CD41^+^ cells also initiated CD45^+^ expression and continued to mature toward CD41^−^CD45^+^ cells. Without *Runx1* induction, the proportion of cells expressing low levels of CD41 was also strongly increased by HOXB4. However, these cells did not undergo EHT, further upregulate CD41 expression, or even generate CD45^+^ cells. Instead, the proportion of CD41^+^ cells strongly diminished over time. Without ectopic human HOXB4, a much smaller proportion of cells became CD41^+^ or CD45^+^ after induction of *Runx1*, which was in line with the significantly reduced number of HE colonies present in the cultures. Moreover, transcription of the hemato-endothelial genes *Scl/Tal1*, *Gata2*, *Lmo2*, and *Cdh5* (encoding VE-cadherin) and *Pecam1* ([@bib13]) was upregulated by HOXB4 in the absence of *Runx1* ([Figure S3](#mmc1){ref-type="supplementary-material"}B). After induction of *Runx1*, expression of the key hematopoietic TF *Pu.1* ([@bib15]) was induced, as well as *Gfi1* and *Gfi1b*, two direct downstream effectors of RUNX1, which are necessary for the early and late phase of EHT, respectively ([@bib27], [@bib56]). Noteworthy, induction of *Runx1* alone without HOXB4 led to a transcriptional repression of the aforementioned hemato-endothelial genes, likely mediated by RUNX1 itself or GFI1 ([@bib27]). Taken together, these results prove that the endothelial structures promoted by HOXB4 are indeed hemogenic.Figure 2Formation of HE Colonies Is Promoted by HOXB4(A) During co-culture on OP9 cells, circular sheet colonies were formed by the dissociated CCE-ESC-derived EBs (eGFP-HOXB4 transduced), which were commonly associated with hematopoietic suspension cell clusters. Left panel: phase contrast; right panel: eGFP-fluorescence. Scale bars, 100 μm.(B) The observed endothelial colonies expressed VE-cadherin, CD31, and were capable of acetylated low-density lipoprotein (LDL) (DilAcLDL) uptake. Scale bars, 100 μm.(C) The number of endothelial CD31^+^ and DilAcLDL^+^ colonies strongly increased when HOXB4 was ectopically expressed. Average colony numbers per 10^5^ seeded cells are represented as columns, error bars represent SD of n = 3 independent experiments.(D) iRunx-ESCs with and without a 4-hydroxytamoxifen (Tam) inducible form of HOXB4 (vector FMEV-tdTomato-2A-HOXB4^ERT^) were differentiated as EBs for 6 days, dissociated, and co-cultured on OP9 stroma cells for further 4 days without *Runx1* induction (no addition of doxycycline); n = 9 and 4 independent experiments for controls, n = 7 for HOXB4. Without HOXB4 induction, the number of HE colonies per 10^5^ seeded EB cells was comparable with unmanipulated controls. When HOXB4 was induced throughout differentiation, the number of HE colonies increased approximately 30-fold (p \< 10^−4^). The p values were calculated using the two-sided, unpaired Student\'s t test with a significance level defined as 0.05.(E) Flow cytometric analysis showing the proportion of CD41^+^ and CD45^+^ cells in OP9 co-cultures after 5 and 12 days. Dissociated iRunx EBd6 were co-cultured on OP9 cells with or without addition of doxycycline (0.1 μg/mL) to induce *Runx1* expression and with or without addition of 100 nM Tam for induction of HOXB4^ERT^ (FMEV-tdTomato-2A-HOXB4^ERT^). Induction of *Runx1* and HOXB4^ERT^ started from day 3 of EB development on until day 5 of OP9 co-culture. Cells were harvested after 5 or 12 days of OP9 co-culture, and the proportion of CD41- and CD45-expressing cells determined by flow cytometry. OP9 cells were removed with an anti-CD140b antibody.

HOXB4 Primes Hemangioblast Progeny toward the Hemogenic Endothelium {#sec2.3}
-------------------------------------------------------------------

Because the number of HE colony-forming cells was increased by HOXB4, we asked whether it expands its upstream progenitor, the hemangioblast ([@bib28]). To determine its frequencies, we performed blast colony-forming assays ([@bib7]). As the frequency of FLK-1^+^ hemangioblasts (blast colony-forming cells \[BL-CFCs\]) was highest around day 3.5 of EB development, we isolated FLK-1^+^ iRunx cells at that time point and performed blast colony-forming assays with or without HOXB4 expressed constitutively (HOX^const^) or in an inducible form, HOX^ERT^ (4-hydroxytamoxifen \[Tam\]-inducible HOXB4-ERT2) ([Figure 3](#fig3){ref-type="fig"}A). Two morphologically distinct types of colonies can be detected in this assay, smooth colonies and blast colonies ([@bib28]). However, the average numbers of both types of colonies did not significantly change by ectopic HOXB4 expression. The colony frequencies were all at approximately 1%, which is the commonly reported range ([Figures 3](#fig3){ref-type="fig"}B and 3D) ([@bib10]). Thus, HOXB4 did not promote the formation of BL-CFCs. We therefore asked whether HOXB4 alters their fate as an explanation for the observed increase in the number of HE cells. For this purpose, we evaluated the developmental fate of pooled colonies by subjecting those cells into an angiogenic tube formation assay in Matrigel ([@bib2]). While control iRunx cells and non-activated HOXB4^ERT^ cells (without Tam) formed meshworks with cords of tubules in Matrigel, cells expressing HOXB4 formed a morphologically distinct mesh of flattened cells without a tubular network ([Figure 3](#fig3){ref-type="fig"}C). An aliquot was also placed onto OP9 cells to quantify HE colonies. The number of HE colonies was again over 100-fold higher when HOXB4 was constitutively expressed or induced ([Figure 3](#fig3){ref-type="fig"}E), therefore suggesting that HOXB4 may alter the developmental fate of either hemangioblasts or their progeny contained within the blast/smooth colonies. To examine this more closely, we induced HOXB4^ERT^ either from the beginning of EB differentiation on, or at different time points prior to and after the blast colony-forming stage in differentiating iRunx cells. Again, the numbers of blast and smooth colonies did not change whether or not HOXB4 was induced in FLK-1^+^ cells ([Figures 4](#fig4){ref-type="fig"}A and 4C). When HOXB4 was first induced after their dissociation, the number of HE structures subsequently formed on OP9 stroma did not increase ([Figure 4](#fig4){ref-type="fig"}B, −/−/+ Tam). In contrast, when HOXB4 was already induced during the formation of blast/smooth colonies, the number of subsequent HE colonies markedly increased ([Figure 4](#fig4){ref-type="fig"}B, −/+/− Tam). Continuous presence throughout blast and HE colony formation even led to a further increase of HE colonies on OP9 cells ([Figure 4](#fig4){ref-type="fig"}B, −/+/+ Tam). These results indicate that HOXB4 primarily acts during the blast culture phase, in cells downstream of the hemangioblast, which may present immediate colony-forming precursors of the HE.Figure 3HOXB4 Does Not Alter Blast Colony-Forming Cell (Hemangioblast) Frequencies(A) Depicted is an overview of FLK-1^+^ hemangioblast frequency determination, subsequent HE quantitation, and evaluation of tube formation propensities. iRunx cells were differentiated as EBs for 3.5 days, FLK-1^+^ cells with and without ectopically expressed HOXB4 were sorted, and 50,000 cells each subjected to blast colony-forming assays to retrospectively quantify the number of hemangioblasts 4 days later. All colonies were harvested, dissociated, and 50,000 cells each placed onto OP9 stroma cells to determine the number of HE colony-forming progenitors 3 days later. A total of 40,000 cells each were placed into a Matrigel-based tube formation assays. All assays were performed at least in triplicate, without *Runx1* induction.(B) Ectopic HOXB4 expression did not significantly alter the total number of colonies. For statistical analysis, p values were calculated based on the two-sided, unpaired Student\'s t test, n = 6--12; the significance level was defined as p \< 0.05. The individual colony numbers are shown as symbols, the arithmetic means depicted as lines.(C) HOXB4 altered the ability of blast colony cells to form tubes. Instead of the small, thin tubular network observed in the controls (Ctrl and HOXB4^ERT^ without Tam), flat, adherent structures were formed with differing morphologies. The mid-panels show magnifications of the areas indicated in the left pictures. Scale bars, 50 μm.(D and E) Frequencies of BL-CFCs (arithmetic means, as described in B) (D) and of HE colonies (arithmetic means of n = 3 independent replicates) without HOXB4 induction (HOXB4^ERT^ no Tam) or with constitutively expressed (HOXB4 const) or induced HOXB4 (HOXB4^ERT^ + Tam) (E).Figure 4The Progeny of Hemangioblasts Is the Prime Target of HOXB4 Activity(A) Ectopic HOXB4 activity was induced by addition of Tam at the indicated stages of iRunx-ESC differentiation. BL-CFC assays were performed with 10,000 FLK-1^+^ iRunx EBd3.5 cells each, +/− Tam.(B) The total number of colonies was counted 4 days later, the average numbers of n = 3 independent experiments are indicated. +,+,+, Tam (HOXB4) was continuously present; −,−,−, without Tam (no HOXB4 induction); −/−/+, HOXB4 was first induced after dissociation of colonies; −/+/+, HOXB4 was first induced in EBd3.5 FLK-1-sorted cells; −/+/−, HOXB4 was only transiently induced during blast colony formation by FLK-1^+^ hemangioblasts.(C) Individual colony numbers and arithmetic means (bars): −/−, no Tam; −/+, induction of HOXB4 in FLK-1-sorted cells; +/+, continuously induced HOXB4. For statistical analysis, an unpaired, two-sided t test with Welch\'s correction (n = 6) was performed. The p values of individual comparisons are indicated with a significance level defined as p \< 0.05. To evaluate HE formation, 10,000 cells of pooled, dissociated colonies were placed onto OP9 stroma cells +/− Tam. The numbers of HE colonies grown on OP9 cells after 3 days are shown.

HOXB4 Induces Hemogenic Endothelial Cells without Affecting Endothelial Cell Development {#sec2.4}
----------------------------------------------------------------------------------------

Fate mapping experiments in embryos have suggested that hematopoietic and endothelial cells specify independently from each other or, alternatively, separate early during development ([@bib40], [@bib57]). Both populations are contained within an FLK-1^+^PDGFRα^−^ population, *in vivo* and *in vitro*, which derives from *Etv2*^+^(*ER71*)^+^ mesodermal progenitors ([@bib20], [@bib31], [@bib44], [@bib45], [@bib60]). To test whether HOXB4 re-specifies endothelial cells toward the hematopoietic fate during early *Runx1-*independent stages, we deposited single FLK-1^+^ PDGFRα^−^ cells from d4 iRunx EBs on OP9 stromal cells and determined the frequencies of circular, cobblestone-like CD31^+^ (Pecam1) hemogenic and of elongated endothelial colonies formed after further 4 days. We then asked whether the frequencies change after induction of HOXB4 ([Figure 5](#fig5){ref-type="fig"}A). Irrespective if HOXB4 was induced or not, the frequencies of CD31^+^ endothelial, strand-like colonies were unchanged ([Figures 5](#fig5){ref-type="fig"}B and 5C). In contrast, when HOXB4 was induced, either throughout differentiation or immediately after single-cell deposition, the number of circular HE colonies significantly increased compared with the non-induced control. Possible explanations are that HOXB4 either mediated enhanced proliferation of HE precursors or, alternatively, protected them from apoptosis. To test these possibilities we induced HOXB4 in FLK-1^+^ cells purified from day 3.5 EBs and subjected them to blast culture conditions. After 24 and 48 hr, we either pulse-labeled replicating DNA with EdU for 2.5 hr or determined the proportion of apoptotic cells by annexin V and DAPI staining. Neither proliferation nor apoptosis of FLK-1^+^ progenitor cells was altered after induction of HOXB4 ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 5HOXB4 Does Not Re-specify Endothelial Cells to a Hematopoietic Fate(A) iRunx ESCs expressing tamoxifen-inducible HOXB4 (tdTomato-2A-HOXB4^ERT^) were differentiated as EBs for 4 days, dissociated, and single FLK-1^+^PDGFRα^−^ cells deposited and co-cultured with OP9 cells in 96-well plates. After a further 4 days, CD31^+^ tdTomato/HOXB4^+^ colonies were counted and qualified either as \"endothelial colony\" or \"HE colony.\"(B) Typical colony morphologies. Scale bars, 100 μm.(C) Quantification of endothelial and HE colonies formed by single deposited cells +/− HOXB4 induction. --Tam, without HOXB4^ERT^ induction; +Tam, permanent induction of HOXB4^ERT^. +Tam post sort, induction after single-cell deposition. The p values as calculated by Student\'s t test, paired and two-sided, with a significance level defined as 0.05, are indicated above. Forms and colors indicate endothelial and HE colonies grown on the same 96-well plate.

Taken together, the results indicate the following: (1) HOXB4 does not re-specify FLK-1^+^PDGFRα^−^ endothelial cells toward a hematopoietic fate because, otherwise, the endothelial colony numbers would have decreased after HOXB4 induction. (2) Induction of HOXB4 in single mesodermal FLK-1^+^ cells does not enhance their proliferative activity or inhibit apoptosis, but instead activates an endogenous program allowing them to form HE colonies and realize their hematopoietic potential as soon as *Runx1* is switched on.

The Transcriptional Signature of ESC-Derived Mesodermal Cells Ectopically Expressing HOXB4 Indicates the Acquisition of a Hemogenic Endothelial Fate {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------------------------------

As HOXB4 does not appear to re-specify endothelial cells but, instead, activates a hematogenic program in single FLK-1^+^PDGFRα^−^ cells, we asked how HOXB4 rewires the transcriptional regulatory circuits during a RUNX1-independent stage of hematopoietic development. To answer that question, we compared the transcriptional profiles of FLK-1^+^PDGFRα^−^ cell populations purified from iRunx day 4 EBs with and without ectopic HOXB4 expression. Among mRNAs that were upregulated (321), we found transcripts that are necessary for hematopoietic specification, such as *Scl/Tal1*, *Gata2*, *Fli1*, *Tie2*, *Erg*, *Kit*, *Egfl7*, *Lyl1*, *Myb*, *Sox7*, or *Hhex*, as well as transcripts encoding hemato-endothelial surface molecules *Cdh5* (VE-cadherin), *CD34*, or *CD109* ([Figures 6](#fig6){ref-type="fig"}A and 6B; [Table S1](#mmc2){ref-type="supplementary-material"}). Notably, most of the so-called heptad TF-encoding genes, which co-operate to promote hematopoiesis, were significantly upregulated in the HOXB4-iRunx cells (*Tal1, Lyl1, Fli1, Gata2, Erg*, and *Lmo2*, except *Runx1*) ([Figure 6](#fig6){ref-type="fig"}B) ([@bib63]). Downregulated mRNAs (178) comprised transcripts that encode proteins associated with mesodermal and cardiovascular development, such as *Hand1*, *Mixl1*, *Gata4*, *Foxf1*, *Foxh1*, *Lef1*, *Etv2*, *Fgf15*, or *Tgfb2* ([Figure 6](#fig6){ref-type="fig"}A, lower panel; [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 6Gene Expression Profiling of FLK-1^+^PDGFRα^−^ Cells(A) Heatmap showing the top 32 genes (fold-change ranked) either up- or downregulated in FLK-1^+^PDGFRα^−^ cell populations from iRunx day 4 EBs without (ctrl) or with ectopically expressed HOXB4. Genes were considered differentially expressed if they met two criteria: q ≤ 0.2 and fold-change ≥ 2.0 (499 genes) (for full list see [Table S1](#mmc2){ref-type="supplementary-material"}).(B) Heatmap for the expression of heptad transcription factors.(C) GSEA using gene sets specific for mesodermal progenitors (\[MPs\] top panel) compared with endothelial cells (ECs), ECs compared with blood progenitors (\[BPs\] second panel) and endothelial cells compared with mesodermal progenitors (third panel) ([@bib49]); E8.5 RUNX^−^ endothelial cells (RUNX1-neg. ECs) compared with RUNX1^+^ endothelial cells (RUNX1-pos. ECs, fourth panel) ([@bib52]) and E10 hemogenic endothelial cells (HECs) compared with endothelial cells (ECs, fifth panel) ([@bib50]). Genes were drawn according to their rank from left (high expression in control) to right (high expression in HOXB4-expressing cells) and gene sets plotted on top with each black bar representing a gene. The enrichment score is plotted in on the vertical axis.

To test if these cells displayed a gene expression signature corresponding to a hemato-endothelial precursor, *in vivo*, we first asked which mesodermal cell type of the gastrulating embryo the iRunx-derived cells +/− HOXB4 most closely relate to molecularly ([@bib49]). Gene set enrichment analysis (GSEA) ([@bib51]) uncovered that FLK-1^+^PDGFRα^−^RUNX1^−^ cells without ectopic HOXB4 most closely resembled a transcriptional signature of early mesodermal progenitors of the neural plate stage (E7.5). In contrast, cells expressing activated HOXB4 displayed a significant enrichment of genes expressed in hemato-endothelial progenitors of the head-fold stage (E7.75) ([Figure 6](#fig6){ref-type="fig"}C; [Table S2](#mmc3){ref-type="supplementary-material"}). To further refine the analysis we asked how closely these iRunx-derived cells resembled hemato-endothelial cells of E8.5 transgenic *Runx1*-reporter ("+23GFP") mouse embryos ([@bib52]). GSEA indicated a closer relationship of FLK-1^+^PDGFRα^−^ EBd4 iRunx cells to 23GFP^−^/RUNX1^−^ hemato-endothelial cells then to GFP^+^/RUNX1^+^ HE cells ([Figure 6](#fig6){ref-type="fig"}C; [Table S2](#mmc3){ref-type="supplementary-material"}). This was not surprising, as *Runx1* was not induced in the iRunx cells. However, the results point out that ectopic HOXB4 cannot initiate those transcriptional programs critical for subsequent steps of hematopoietic development without the activity of RUNX1. We finally asked whether the transcriptome of HOXB4 cells rather displayed an endothelial or HE signature using gene sets from dorsal aorta cells of E10 transgenic *Sca1*-reporter (*Ly6aGFP*) mice ([@bib50]). Although *Runx1* was not induced in the iRunx cells, GSEA clearly indicated similarity of HOXB4-expressing EBd4 iRunx cells to dorsal aorta-resident HE cells ([Figure 6](#fig6){ref-type="fig"}C; [Table S2](#mmc3){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

Two main concepts exist with regard to how the HE is formed during embryonic development. One is based on a dichotomic model in which binary fate decisions happen during cell divisions throughout development. The FLK-1^+^ hemangioblast, a progenitor cell thought to generate all vascular endothelial and hematopoietic cells fits to the idea ([@bib7], [@bib28], [@bib36]). The other possibility is that endothelial and hematopoietic lineages separate during an earlier developmental stage and develop independently of each other. This concept is supported by cell tracing analysis in embryos ([@bib40], [@bib57]). In that case, the hemangioblast could present a specialized, transiently existing endothelial cell with the competence to acquire a hematopoietic fate upon environmental cues mediated, for example, by Notch or Wnt signaling ([@bib43]).

When ectopically expressing HOXB4 in differentiating iRunx cells, we did not observe a significant change in the numbers of blast colony-forming hemangioblasts. However, when we tested the developmental competence of the progeny of these cells to form HE colonies, we observed a strong increase in their numbers when HOXB4 was induced during blast colony formation of FLK-1^+^ cells. Hence, HOXB4 appeared to promote the hematopoietic fate in HE precursors downstream of the hemangioblast. Supporting this idea, deposition of single FLK-1^+^PDGFRα^−^ cells and induction of HOXB4 significantly promoted the formation of circular, cobblestone-like HE colonies, which underwent EHT after induction of *Runx1*. Interestingly, the number of cord-formed endothelial colonies was unchanged, irrespective if HOXB4 was activated or not. If HOXB4 would directly act as a fate determinant in hemangioblasts, the increase of HE colonies must have been accompanied by a concomitant decrease in the number of endothelial colonies. However, that was not the case, thus supporting the interpretation that HOXB4 acts after the hemangioblast stage in precursors of the HE.

Genome-wide transcriptional profiling revealed that HOXB4 induced the expression of a plethora of genes essential for hematopoiesis. Particularly, most of the heptad-TF genes were upregulated during early differentiation of iRunx-ESCs (except *Runx1*). The encoded TFs are known to co-operatively regulate genes essential for hematopoietic development ([@bib63]). Importantly, HOXB4 has previously been shown to physically bind upstream of all of these seven genes ([@bib11]). For example, it directly binds to the conserved +85 kb enhancer element of *Erg* ([@bib35], [@bib64]), which is also bound by most of the heptad TFs ([@bib48]). Furthermore, HOXB4 binds to DNA in close proximity to the TFs FLI-1, MEIS1, RUNX1, and SCL ([@bib11]), strongly implying its participation in a TF complex regulating common hematopoietic target genes. GSEA with gene sets derived from hematopoietic tissues that had been isolated by different means and different stages (E7.5--E10) of embryonic development ([@bib49], [@bib50], [@bib52]) indicated that HOXB4^+^FLK-1^+^PDGFRα^−^ cells most closely resembled HE cells of the dorsal aorta in E10 embryos. Given that endogenous mouse *HoxB4* is also expressed at low levels around this stage, *in vivo* ([@bib35]), ectopic overexpression of human HOXB4 in differentiating ESCs may simply represent a fortification of embryonic hematopoiesis.

Our results with HOXB4 may be paradigmatic for the activities of all HOX4 paralogs, as ectopic expression of the other orthologs HOXA4, C4, and D4 similarly enhanced hematopoietic development of differentiating ESCs ([@bib14]). HOXB4 directly binds to a region between the proximal (P2) and distal (P1) promoters of *Runx1*, which correlates with demethylation and activation of the P1 promoter ([@bib61]). This may probably explain our observation of *Runx1* upregulation in a small subpopulation of ESC-derived HE cells, *in vitro* ([@bib55]). How homeotic selector proteins mechanistically influence cell fate decisions during development is not well understood yet. It appears that their activities as activators or repressors of transcription depend on their expression levels, the cell type they are expressed in, and probably also the microenvironment of the cells ([@bib23], [@bib42], [@bib46], [@bib47], [@bib62]). It could be envisioned that these master switches of development integrate signaling events allowing for the realization of certain genetic programs by epigenetically promoting enhancer activation or decommission.

In the present work we have shown that HOXB4 first unfolds its hematopoiesis-promoting activity in HE precursors (summarized in [Figure 7](#fig7){ref-type="fig"}). By inducing a hematopoietic program in those cells, HOXB4 promotes the acquisition of an HE identity and, thus, enforces early hematopoietic development. It remains to be shown if this also holds true for differentiating human pluripotent stem cells, as this would open the possibility to enhance the generation of patient-specific HSPCs. In fact, a recent report strongly suggests that ectopic HOXB4 expression also promotes hematopoietic development of human ESCs ([@bib17]), therefore supporting the idea of what is true for mouse hematopoietic development also holds true for humans.Figure 7Model of HOXB4 Activity during Pluripotent Stem Cell DifferentiationDuring mouse ESC differentiation, HOXB4 appears to promote hematopoietic commitment after the hemangioblast stage in VE-Cad^+^FLK-1^+^TIE2^+^KIT^+^CD31^+^ precursors of HE cells by upregulating the expression of key hematopoietic transcription factors, in a RUNX1-independent fashion. Importantly, our results indicate that this does not happen at the expense of endothelial cells. These results are also compatible with the notion that (at least a part of) endothelial cells develop hemangioblast-independently ([@bib40], [@bib57]).

Experimental Procedures {#sec4}
=======================

For production of retroviral vectors, ESC culture, hematopoietic differentiation, mouse transplantation, colony-forming assays, gene expression analysis, and time-lapse microscopy, see [Supplemental Information](#app2). All animal experiments were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV) (reference number 84-02.04.2013.A350) and were performed according to official guidelines and regulations.

Blast Colony-Forming Assays {#sec4.1}
---------------------------

Blast colony assays were performed as described ([@bib22]). In brief, 5 × 10^5^ ESCs were differentiated as EBs for 3.5 days, dissociated and FLK-1^+^ cells sorted by flow cytometry (FACSAria III, BD Biosciences). Cells were subsequently cultured at a concentration of 5 × 10^4^ cells/mL for 4--5 days in IMDM containing 10% (v/v) fetal calf serum (GE Healthcare), 2 mM L-glutamine, 20% (v/v) D4T conditioned medium, 1% (v/v) penicillin/streptomycin, 4.5 × 10^−4^ M MTG, 25 ng/mL ascorbic acid, 300 μg/mL holotransferrin (Sigma-Aldrich), 10 ng/mL rhIL-6, 5 ng/mL rhVEGF, 25% methylcellulose solution, under hypoxic conditions (3% O~2~) at 37°C in a H~2~O saturated atmosphere.

Tube Formation Assay {#sec4.2}
--------------------

To assess the angiogenic activity of cells contained within blast colonies, 4 × 10^4^ cells were cultured in μ-Slide Angiogenesis chambers (ibidi) filled with 10 μL Matrigel matrix (Corning Life Sciences) for 19 hr at 37°C in H~2~O saturated atmosphere, 3% O~2~, 5% CO~2~.

Flow Cytometry Analysis and Cell Sorting {#sec4.3}
----------------------------------------

Differentiating ESCs, bone marrow and peripheral blood of transplanted mice were analyzed by flow cytometry using fluorochrome-conjugated monoclonal antibodies. Details regarding employed antibodies (specificities, manufacturer, catalog numbers) are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} section.

For FACS analysis, dead cells were excluded by DAPI staining. Gates were set based on control samples stained according to the Fluorescence Minus One method. Flow cytometry measurements and single-cell sorting were performed on a FACSAria III instrument (BD Biosciences) using FACSDiva software, datasets were analyzed using FlowJo software (Tree Star).

Magnet-Activated Cell Sorting {#sec4.4}
-----------------------------

For removal of stroma cells, magnet-activated cell sorting (MACS) technology was used (Miltenyi). Harvested cells were incubated either with Feeder Removal MicroBeads (for removal of CF1-MEFs) or with an anti-CD140b PE-labeled mAB (OP9) and anti-PE microbeads, and subsequently depleted with MACS LS Columns, according to the manufacturer\'s recommendations.

Transcriptome Analysis {#sec4.5}
----------------------

iRunx EBd4 were dissociated and FLK-1^+^PDFGRα^−^ cells with or without retroviral expression of tdTomato/HOXB4 were sorted by FACS. Total RNA was extracted using TRIzol and subsequently purified with RNeasy columns (QIAGEN). Each sample (500 ng) was converted into fragmented, biotinylated cDNA hybridized to a microarray chip (Clariome D MTA 1.0) and fluorescently labeled according to the standard protocol (Affymetrix, Santa Clara, CA). Raw data were processed in Expression Console (Affymetrix) using RMA normalization and expression values calculated for each Refseq-annotated gene (23,781 total). The expression data were processed in Gene Pattern (Broad Institute, Cambridge, MA). Non-expressed genes were filtered out, and the resulting expression matrix was analyzed with the comparative marker module. GSEA (Broad Institute) was performed as described previously ([@bib51]). Genes sets ([Table S2](#mmc3){ref-type="supplementary-material"}) were derived from associated publications as indicated in the text.

Statistical Analysis {#sec4.6}
--------------------

Significance testing of differences between mean values was performed by calculating p values using the two-sided unpaired, Student\'s t test. Significance levels were defined as p \< 0.05. For all calculations, GraphPad Prism6 software (GraphPad, CA, USA) was used.
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